Dublin, Aug. 08, 2023 (GLOBE NEWSWIRE) -- The "Global COVID-19 Clinical Trials Market Forecast 2023-2030" report has been added to ResearchAndMarkets.com's offering.
The Global COVID-19 Clinical Trials Market is estimated to have been valued at USD 5.21 billion in 2022, with a projected growth to USD 14.84 billion by 2030, at a CAGR of 13.95% from 2023 to 2030.
The report takes into account the ongoing political and economic uncertainty caused by the Russia-Ukraine Conflict in Eastern Europe and its potential impact on demand-supply balances, pricing variants, and import/export and trading. Additionally, it addresses the effects of High Inflation on the global economy and discusses fiscal policies aimed at mitigating its impact on demand, supply, cash flow, and currency exchange.
Market Dynamics
- Drivers
- Rapid Spread of Coronavirus Resulting in a Large Number of Deaths
- Government Support and Grants for COVID-19 Clinical Trials
- Increasing Research and Development (R&D) Initiatives for Effective Therapeutics
- Restraints
- Complexities in Clinical Trial Management and Risk of Side Effects During Trials
- Opportunities
- Collaborative Efforts of Pharma and Technology Firms
- Rising Investment from Importing Countries
- Challenges
- Limited Supportive Infrastructure, Skills, and Technology in Developing Areas Around the World
The market is segmented based on products into Therapeutics and Vaccines, with Vaccines holding the largest market share of 70.81% in 2022, followed by Therapeutics. It is also studied based on the clinical trial phases, including Phase I, Phase II, Phase III, and Phase IV, with Phase III commanding the largest market share of 33.66% in 2022, followed by Phase II.
Region-wise, the market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. Europe, Middle East & Africa held the largest market share of 35.57% in 2022, followed by Americas.
The report provides a detailed analysis of vendors using the FPNV Positioning Matrix, which assesses key metrics within Business Strategy and Product Satisfaction, categorizing vendors into four quadrants: Forefront (F), Pathfinder (P), Niche (N), or Vital (V), based on their level of success.
Market Share Analysis offers insights into the current state of vendors in the market space by comparing their contributions to overall revenue, customer base, and other key metrics. This analysis sheds light on the competitive landscape, market share accumulation, fragmentation dominance, and amalgamation traits over the studied period.
The report also covers aspects like market penetration, market development, market diversification, and market trends, providing comprehensive information on key players' strategies, new product launches, untapped geographies, recent developments, and investments.
Moreover, Competitive Assessment & Intelligence offers an exhaustive evaluation of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of leading players. Product Development & Innovation provides insights on future technologies, R&D activities, and breakthrough product developments.
Overall, the report offers valuable insights into the Global COVID-19 Clinical Trials Market, helping stakeholders make informed decisions based on specific needs and market conditions.
Key Attributes
| Report Attribute | Details |
| No. of Pages | 185 |
| Forecast Period | 2023-2030 |
| Estimated Market Value (USD) in 2023 | $5.95 Billion |
| Forecasted Market Value (USD) by 2030 | $14.84 Billion |
| Compound Annual Growth Rate | 13.9% |
| Regions Covered | Global |
Key Topics Covered
1. Preface
2. Research Methodology
3. Executive Summary
4. Market Overview
5. Market Insights
6. COVID-19 Clinical Trials Market, by Product
7. COVID-19 Clinical Trials Market, by Phase
8. Americas COVID-19 Clinical Trials Market
9. Asia-Pacific COVID-19 Clinical Trials Market
10. Europe, Middle East & Africa COVID-19 Clinical Trials Market
11. Competitive Landscape
12. Competitive Portfolio
Companies Mentioned
- AbbVie Inc.
- Bharat Biotech Ltd.
- BioNTech SE
- Clario
- Gilead Sciences, Inc.
- GlaxoSmithKline PLC
- ICON PLC
- Inovio Pharmaceuticals, Inc.
- IQVIA Inc.
- Johnson & Johnson Services, Inc.
- Laboratory Corporation of America Holdings
- Medidata Solutions
- Moderna, Inc.
- Novartis AG
- Novavax, Inc.
- Novotech
- PAREXEL International Corporation
- Pfizer Inc.
- PPD, Inc.
- Quanticate
- Takeda Pharmaceutical Company Limited
For more information about this report visit https://www.researchandmarkets.com/r/6ylro
Attachment
